BeiGene is a global biotechnology company that specializes in the development of drugs for cancer treatment. Founded in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in Asia, North America, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib. BeiGene was founded in late 2010 by Xiaodong Wang, a Chinese-American scientist, and John V. Oyler, an American entrepreneur who serves as the company's chief executive officer and chairman. As of early 2023, the company had more than 9,000 employees worldwide. While many pharmaceutical drugs are manufactured in China, almost all early research and development for the drugs takes place elsewhere. Wang and Oyler envisioned a biopharmaceutical company with strong ties to China to conduct research and development. They chose to focus specifically on cancer treatment. More information...
According to PR-model, beigene.com is ranked 1,279,462nd in multilingual Wikipedia, in particular this website is ranked 169,274th in German Wikipedia.
The website is placed before fapsp.com.br and after cc-larmont.fr in the BestRef global ranking of the most important sources of Wikipedia.
